Seagen Inc. (SGEN)
228.74
-0.16 (-0.07%)
At close: Dec 13, 2023, 9:00 PM
-0.07% (1D)
| Bid | n/a |
| Market Cap | 43.15B |
| Revenue (ttm) | 2.3B |
| Net Income (ttm) | -750.23M |
| EPS (ttm) | -4 |
| PE Ratio (ttm) | -57.185 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 19,392,808 |
| Avg. Volume (20D) | 1,634,027 |
| Open | 228.93 |
| Previous Close | 228.90 |
| Day's Range | 228.74 - 228.96 |
| 52-Week Range | 126.47 - 228.96 |
| Beta | 0.32 |
About SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibit...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2001
Employees 3,256
Stock Exchange NASDAQ
Ticker Symbol SGEN
Website https://www.seagen.com